115 results about "Assisted reproductive technology" patented technology

The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, or relaxin receptor activity.

This invention discloses a substantially protein-free cell culture solution for assisted reproductive technologies and methods of use thereof.

The invention relates to an extremely-low sperm freezing protective agent and application thereof. The protective agent is prepared from the following ingredients: sodium chloride, potassium chloride, magnesium sulfate, monopotassium phosphate, calcium chloride, fructose, trehalose, sodium citrate, glycin, glutamine, pentoxifylline, vitamin E, HAS (human serum albumin), glycerin and gentamicin sulphate. The extremely-low sperm freezing protective agent can protect less sperms with low activity and without forward activity ability in seminal fluid, can remarkably improve the activity ability of the sperms which swing weakly and cannot move forwards in seminal fluid after freezing and thawing, has no obvious influence on the physiological function of the sperms, has high freezing anabiosis rate, can be used for cryopreservation of less and weak sperms, testicle sperms and epididymis sperms, and contributes to the successful development of assisted reproductive technology.

The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.

The invention relates to the field of genetic diagnosis and human assisted reproduction, and more particularly relates to an embryo pre-implantation genetic diagnosis technique (PGD). According to the method provided by the invention, for patients suffering from chromosomal balanced translocation (including reciprocal translocation and Robertson translocation) and mates thereof, family haplotype linkage analysis is performed on the chromosomes of the embryos obtained by in vitro fertilization and the relatives of the translocation carrier, the embryos with chromosomal balanced translocation and the embryos with normal chromosomes can be rapidly, simply and accurately distinguished, and at the same time, the chromosome copy number variation of the embryo is screened, so that the clinical pregnancy rate is improved, the genetic transmission of the chromosomal balanced translocation to the next generation is timely blocked before embryo implantation, and thus the development and progress of the human assisted reproductive technology are promoted to a certain extent.

The invention discloses an ovum and embryo treating fluid and a preparation method thereof. The ovum and embryo treating fluid contains composition and a sterilizing agent used for carrying out treatment and culture on an ovum and an oosperm, and an indicator can be selectively added. Indicators of the ovum and embryo treating fluid meet standards of an in vitro culture solution, the ovum and embryo treating fluid is safe to use, and whether the culture solution goes bad or not can be easily judged, and a strong guarantee is provided for an assisted reproductive technology.

The invention relates to a sperm washing liquid and a preparation method thereof and belongs to the technical field of human assisted reproduction. The sperm washing liquid is prepared by dissolving heparin sodium dry powder or heparin sodium salt solution in a salt solution containing antibiotics and indicator. Heparin sodium is added into the sperm washing liquid, and by combination with a receptor on the surface of sperm, heparin can activate a signal transduction system coupled with the receptor, so a capacity function of sperm mitochondria and calcium ion internal flow are improved mildly and effectively, sperm activity is improved, and not only can the artificial insemination success rate be improved, but also safety of the assisted reproductive technology is strongly ensured.

A 22 kD sperm protein, SP22, correlates with fertility and predicts fertility in males. The protein can be assayed to detect decreases in fertility resulting from exposure to toxicants and pollutants which are known or suspected to decrease fertility. In an antibody is generated to this protein, the antibody recognition by sperm in an epididymal sperm sample or ejaculate would reflect the fertility of the sample. This antibody can be used as a contraceptive to inactivate sperm, screen for toxicity, select animals for artificial insemination, and select men for assisted reproductive technologies. The protein itself can be inactivated by gene knockout, which is another approach to contraception, or the protein can be added to sperm from infertile men to make fertility techniques more feasible.

The invention discloses a protein extraction and treatment process at different time points (including early, middle and late periods of secretion: LH_2, LH_5, LH_7, LH_9, LH_10 and LH_12, and LH_0 on the day of injection of hCG) in a human endometrial tissue secretion period, and a protein spectrum and a phosphorylation modification mass spectrum are carried out to obtain molecular expression modes at different time points in the secretion period. The molecular expression modes can provide a basis for further knowing the dynamic change of the human endometrial tissue secretion period, and is beneficial to judging an endometrial implantation window period and guiding the embryo transplantation time in an assisted reproduction technology.

The invention discloses a sperm brake fluid and a preparation method thereof. The sperm brake fluid contains a combination, a fungicide and an indicator which carry out treatment on sperms. Each index of the sperm brake fluid disclosed by the invention is in compliance with the standards of an in-vitro culture solution, the sperm brake fluid is safe in use, and whether the culture solution is deteriorated is easily judged, thereby providing a powerful guarantee for an assisted reproductive technology.

The invention belongs to the technical field of assisted reproduction, and relates to an oocyte activating solution and application thereof. The oocyte activating solution comprises 1.1 to 1.8 mg/L ofionomycin, 6 to 12 mg/L of calcium ion carrier A23187, 63 to 94 mug/L of puromycin, 19 to 43 mg/L of 6DMAP, 3.4 to 6.6 mg/L of actinone CHX, 28 to 53 mug/L of phorbol PMA, 7.8 to 12.7 mug/L of inositol triphosphate, 1.5 to 2.4 g/L of SrCl2, 16 to 25 mg/L of heparin, and basic culture medium. The oocyte activating solution can effectively activate oocytes, and is suitable for activating the oocytes after ICSI in an in-vitro fertilization assisted reproduction technology.

The present invention relates to complement proteins, in particular, C3 protein, and methods using the same for enhancing the development of preimplantation mammalian embryos in vitro for use in assisted reproductive technologies. In particular, the present invention relates to supplementation of complement C3 protein, its precursors, fragments, or derivatives, to culture media to improve the development of cultured embryos and, thereby, enhance pregnancy rates of in vitro fertilization.

The present invention provides a method of predicting the probability of a successful pregnancy, either a naturally achieved pregnancy or a pregnancy resulting from an assisted reproductive technology, based on the level of L-selectin ligand expressed by uterine epithelial cells and/or the level of L-selectin expressed by an embryo in vitro. The invention further provides methods of inhibiting cell adhesion between a trophoblast and a uterine epithelial cell. Methods of inhibiting cell adhesion between a trophoblast and a uterine epithelial cell are useful to inhibit pregnancy. The invention further provides methods of assessing in vitro embryo quality. The invention further provides methods of predicting the probability of continued success of a pregnancy during the first 16 weeks of gestation.

The invention relates to the technical field of assisted reproduction, and discloses a cryoprotectant and an application thereof, a sperm refrigerating fluid and a preparation method of the sperm refrigerating fluid. The sperm refrigerating fluid comprises a cryoprotectant, a composition and a basic culture solution, wherein the cryoprotectant comprises 0.3 to 1.1 mg/L of paclitaxel, 16 to 22 g/Lof trehalose, 7 to 13 g/L of cane sugar and 80 to 250 mL/L of glycerinum; the composition comprises 12 to 26 mg/L of resveratrol, 0.2 to 1.9 mg/L of reduced glutathione, 436 to 775 mg/L of lecithin, 0.5 to 1.6 mg/L of cholesterol, 9 to 17 mg/L of ATP sodium salt, 11 to 28 mg/L of heparin, 93 to 299 mg/L of phosphatidylserine and 5 to 25 mg/L of coenzyme Q10. The sperm refrigerating fluid can reduce damage of sperms in low-temperature freezing and freezing resuscitation processes, improve vitality of the sperms after freezing resuscitation, prolong survival time of the sperms after freezing resuscitation, promote sperm capacitation and enhance penetrating fertilization capacity of the sperms to egg cells. Thus, the fertilization success rate and blastocyst formation rate of the ova are improved, and finally the effect of improving the pregnancy success rate of the in-vitro fertilization assisted reproduction technology is achieved.

The invention relates to a cleavage culture solution and a preparation method thereof and belongs to the technical field of human assisted reproductive technology. The cleavage culture solution has the advantages that the cleavage culture solution is prepared by adding alanine, aspartic acid, asparagine, glutamic acid, glutamine, glycine, proline, taurine, serine, threonine, tyrosine, methionine,lipoic acid, hyaluronic acid and a chelating agent into a salt solution, the activity and nutrition of an embryo can be kept effectively, the chelating agent can chelate some unnecessary heavy metal ions, the toxicity of the culture solution is lowered, the development of the early embryo can be promoted favorably, the success rate of the assisted reproductive technology is increased, and powerfulguarantee is provided for the safety of the assisted reproductive technology.

The present invention relates to culture media for oocytes and uses thereof. Specifically, media for culturing an oocyte in vitro are disclosed, wherein said media comprise granulocyte macrophage-colony stimulating factor (GM-CSF). The presence of GM-CSF in the media increases the maturation and/or developmental competence of the oocyte making it suitable for use in subsequent assisted reproductive technologies. Methods for increasing the maturation and/or developmental competence of an oocyte are also disclosed.

The invention relates to a mouse denuded oocyte (DO) in vitro maturation technology, belonging to the technical field of biology. The invention is characterized in that a cumulus cell uses cystine and cysteamine to improve GSH synthesis and developmental capacities of the DO and, through cumulus cell co-culture and addition of cysteamine and cystine, an in vitro maturation system is established, which completely recovers the developmental capacity of the DO. The DO is co-cultured with mouse or goat cumulus cells in TCM-199 mature culture fluid added with 100-200 mumol/l of cysteamine and 250-300 mumol/l of cystine, the blastocyst rate reaches the level of mature COC cultured by adding the same mercapto-compound. After transplanting 2-cell embryos from the mature DO through co-culture and from COC respectively, the differences in pregnancy rate and number born are not obvious. The invention, for the first time in the world, establishes an in vitro mature system for completely recovering the developmental capacity of mouse denuded oocyte, which is of great importance in the research and application of both animal embryo engineering and human-assisted reproductive technology.

The invention provides novel non-invasive in vitro methods for assessing the metabolic condition of oocytes and/or embryos with fluorescence lifetime imaging microscope, that can be used, for example, in assessment of oocytes and embryos in assisted reproductive technologies.

The invention discloses auxiliary equipment with a multi-angle adjustment function for a female assisted reproductive technology. The equipment comprises a bracket, a support plate, a first hydraulicdevice and a conveying plate, wherein the support plate is arranged on the inner side of the bracket and fixedly connected with the bracket through bolts, the upper portion of the support plate is provided with the first hydraulic device, the upper portion of the first hydraulic device is provided with a retractable rod, the retractable rod is retractably connected with the first hydraulic device,and the conveying plate is arranged at the upper portion of the retractable rod. According to the auxiliary equipment with the multi-angle adjustment function for the female assisted reproductive technology, a driving chain drives a plurality of roller shafts to rotate, a bed plate at the upper portion is conveyed to the upper portion of an operating table, a lifter is started to drive a drivingrod to ascend, one side of the bed plate is lifted, and correspondingly the bed plate slopes, so that the working pressure of medical staff during carrying of patients is reduced, the height of the bed plate can be adjusted at multiple angles, convenience is provided for the medical staff during adjustment, and the transfer efficiency during an operation is improved.